Active agent delivery device having composite members

• US 20040138610A1
• Filed: 12/24/2003
• Published: 07/15/2004
• Est. Priority Date: 12/26/2002
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Cormier, Michel, Matriano, James, Johnson, Juanita
• Application Number:
  US10/745,995
• Publication Number:
  US 20040138610A1
• Time in Patent Office: Days
• US Class Current: 604/46
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 2037/0046 Solid microneedles
• CPC Class Codes: A61M 2037/0061 Methods for using microneedles
• CPC Class Codes: A61M 37/0015 by using microneedles

Abstract

A device and method are provided for percutaneous transdermal delivery of a biologically active agent by applying a microprojection array to the skin of a person or animal with a system that has a composite applicator tip and/or a composite microprojection array system.

Claims

1. A composite microprojection system, comprising:

a microprojection member having a top surface and a skin distal surface, said microprojection member including a plurality of stratum corneum-piercing microprojections that project from said skin distal surface;

a substantially rigid matrix member disposed on said microprojection member top surface;

a compressible ring disposed on said microprojection member top surface and surrounding said rigid matrix member; and

a backing membrane disposed on said rigid matrix member and compressible ring.

2. The microprojection system of claim 1, wherein each of said plurality of stratum corneum-piercing microprojections has a length less than approximately 500 microns.

3. The microprojection system of claim 1, wherein each of said plurality of stratum corneum-piercing microprojections has a thickness in the range of approximately 5-50 microns.

4. The microprojection system of claim 1, wherein said rigid matrix and said compressible ring form a substantially planar disk.

5. The microprojection system of claim 1, wherein said compressible ring comprises a compressible foam.

6. The microprojection system of claim 5, wherein said compressible foam has a compressibility greater than 50 μ

m.

7. The microprojection system of claim 5, wherein said compressible foam comprises a substantially open-cell foam.

8. The microprojection system of claim 5, wherein said compressible foam comprises a substantially closed-cell foam.

9. The microprojection system of claim 5, wherein said foam comprises a material selected from the group consisting of polyethylene, polyurethane, neoprene, natural rubber, SPR, butyl, butadiene, nitrile, EPDM, ECH, polystyrene, polyester, polyether, polypropylene, EVE, EMA, metallocene resin, PVC, and blends thereof.

10. The microprojection system of claim 1, wherein said microprojection member is coated with a biocompatible coating, said biocompatible coating including at least one biologically active agent.

11. The microprojection system of claim 10, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts.

12. The microprojection system of claim 10, wherein said biologically active agent is selected from the group consisting of conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

13. The microprojection system of claim 10, wherein said biologically active agent is selected from the group consisting of fentanyl, sufentanil, remifentanil and nicotine.

14. The microprojection system of claim 10, wherein each of said plurality of stratum corneum-piercing microprojections includes in the range of 1 microgram to 1 milligram of said biologically active agent.

15. The microprojection system of claim 1, wherein said microprojection member includes a reservoir.

16. The microprojection member of claim 15, wherein said reservoir includes at least one biologically active agent.

17. The microprojection system of claim 16, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts.

18. The microprojection system of claim 16, wherein said biologically active agent is selected from the group consisting of conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

19. The microprojection system of claim 16, wherein said biologically active agent is selected from the group consisting of fentanyl, sufentanil, remifentanil and nicotine.

20. The microprojection system of claim 1, wherein said microprojection member includes an agent-containing matrix.

21. The microprojection system of claim 20, wherein said matrix is disposed proximate said top surface of said microprojection member.

22. The microprojection system of claim 20, wherein said matrix is disposed proximate said skin distal surface of said microprojection member.

23. The microprojection system of claim 20, wherein said matrix includes at least one biologically active agent.

24. The microprojection system of claim 23, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts.

25. The microprojection system of claim 23, wherein said biologically active agent is selected from the group consisting of conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

26. The microprojection system of claim 23, wherein said biologically active agent is selected from the group consisting of fentanyl, sufentanil, remifentanil and nicotine.

27. A composite microprojection system, comprising:

a microprojection member having a top surface and a skin distal surface, said microprojection member including a plurality of stratum corneum-piercing microprojections that project from said skin distal surface, said microprojection member being coated with a biocompatible coating, said biocompatible coating including at least one biologically active agent;

a substantially rigid matrix member disposed on said microprojection member top surface;

a compressible ring disposed on said microprojection member top surface and surrounding said rigid matrix member; and

a backing membrane disposed on said rigid matrix member and compressible ring.

28. The microprojection system of claim 27, wherein each of said plurality of stratum corneum-piercing microprojections has a length less than approximately 500 microns.

29. The microprojection system of claim 27, wherein each of said plurality of stratum corneum-piercing microprojections has a thickness in the range of approximately 5-50 microns.

30. The microprojection system of claim 27, wherein said rigid matrix and said compressible ring form a substantially planar disk.

31. The microprojection system of claim 27, wherein said compressible ring comprises a compressible foam.

32. The microprojection system of claim 31, wherein said foam comprises a material selected from the group consisting of polyethylene, polyurethane, neoprene, natural rubber, SPR, butyl, butadiene, nitrile, EPDM, ECH, polystyrene, polyester, polyether, polypropylene, EVE, EMA, metallocene resin, PVC, and blends thereof.

33. The microprojection system of claim 27, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

34. The microprojection system of claim 33, wherein each of said plurality of stratum corneum-piercing microprojections includes in the range of 1 microgram to 1 milligram of said biologically active agent.

35. A composite microprojection system, comprising:

a microprojection member having a top surface and a skin distal surface, said microprojection member including a plurality of stratum corneum-piercing microprojections that project from said skin distal surface, said microprojection member further including a reservoir containing at least one biologically active agent;

a substantially rigid matrix member disposed on said microprojection member top surface;

a compressible ring disposed on said microprojection member top surface and surrounding said rigid matrix member; and

a backing membrane disposed on said rigid matrix member and compressible ring.

36. The microprojection system of claim 35, wherein each of said plurality of stratum corneum-piercing microprojections has a length less than approximately 500 microns.

37. The microprojection system of claim 35, wherein each of said plurality of stratum corneum-piercing microprojections has a thickness in the range of approximately 5-50 microns.

38. The microprojection system of claim 35, wherein said rigid matrix and said compressible ring form a substantially planar disk.

39. The microprojection system of claim 35, wherein said compressible ring comprises a compressible foam.

40. The microprojection system of claim 39, wherein said foam comprises a material selected from the group consisting of polyethylene, polyurethane, neoprene, natural rubber, SPR, butyl, butadiene, nitrile, EPDM, ECH, polystyrene, polyester, polyether, polypropylene, EVE, EMA, metallocene resin, PVC, and blends thereof.

41. The microprojection system of claim 35, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

42. A composite microprojection system, comprising:

a microprojection member having a top surface and a skin distal surface, said microprojection member including a plurality of stratum corneum-piercing microprojections that project from said skin distal surface, said microprojection member further including an agent-containg matrix, said matrix including at least one biologically active agent;

a substantially rigid matrix member disposed on said microprojection member top surface;

a compressible ring disposed on said microprojection member top surface and surrounding said rigid matrix member; and

a backing membrane disposed on said rigid matrix member and compressible ring.

43. The microprojection system of claim 42, wherein said matrix is disposed proximate said top surface of said microprojection member.

44. The microprojection system of claim 42, wherein said matrix is disposed proximate said skin distal surface of said microprojection member.

45. The microprojection system of claim 42, wherein each of said plurality of stratum corneum-piercing microprojections has a length less than approximately 500 microns.

46. The microprojection system of claim 42, wherein each of said plurality of stratum corneum-piercing microprojections has a thickness in the range of approximately 5-50 microns.

47. The microprojection system of claim 42, wherein said rigid matrix and said compressible ring form a substantially planar disk.

48. The microprojection system of claim 42, wherein said compressible ring comprises a compressible foam.

49. The microprojection system of claim 48, wherein said foam comprises a material selected from the group consisting of polyethylene, polyurethane, neoprene, natural rubber, SPR, butyl, butadiene, nitrile, EPDM, ECH, polystyrene, polyester, polyether, polypropylene, EVE, EMA, metallocene resin, PVC, and blends thereof.

50. The microprojection system of claim 42, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

51. A composite applicator tip for an applicator, the applicator being adapted to apply a microprojection member, the applicator tip comprising:

a tip member adapted to cooperate with the applicator, said tip member having a skin distal surface; and

a compressible member disposed on said tip member skin distal surface.

52. The applicator tip of claim 51, wherein said tip member includes a substantially continuous recessed region on said tip member skin distal surface.

53. The applicator tip of claim, 52, wherein said compressible member is disposed in said recessed region.

54. The applicator tip of claim 51, wherein said compressible member comprises a compressible foam.

55. The applicator tip of claim 54, wherein said compressible foam comprises a substantially open-cell foam.

56. The applicator tip of claim 54, wherein said compressible foam comprises a substantially closed-cell foam.

57. The applicator tip of claim 54, wherein said foam comprises a material selected from the group consisting of polyethylene, polyurethane, neoprene, natural rubber, SPR, butyl, butadiene, nitrile, EPDM, ECH, polystyrene, polyester, polyether, polypropylene, EVE, EMA, metallocene resin, PVC, and blends thereof.

58. A composite applicator tip for an applicator, the applicator being adapted to apply a microprojection member, the applicator tip comprising:

a tip member adapted to cooperate with the applicator, said tip member having a skin distal surface, said tip member including a substantially continuous recessed region on said skin distal surface; and

a compressible member disposed in said recessed region.

59. The applicator tip of claim 58, wherein said recessed region is disposed proximate the outer periphery of said tip member skin distal surface.

60. The applicator tip of claim 58, wherein said compressible member comprises a compressible foam.

61. The applicator tip of claim 60, wherein said foam comprises a material selected from the group consisting of polyethylene, polyurethane, neoprene, natural rubber, SPR, butyl, butadiene, nitrile, EPDM, ECH, polystyrene, polyester, polyether, polypropylene, EVE, EMA, metallocene resin, PVC, and blends thereof.

62. A transdermal delivery system, comprising:

a microprojection member having a top surface and a skin distal surface, said microprojection member including a plurality of stratum corneum-piercing microprojections that project from said skin distal surface, a substantially rigid matrix member disposed on said microprojection member top surface, a compressible ring disposed on said microprojection member top surface and surrounding said rigid matrix member, and a backing membrane disposed on said rigid matrix member and compressible ring; and

an applicator adapted to apply said microprojection member, said applicator including an applicator tip that is adapted to contact said microprojection member when said applicator is employed to apply said microprojection member.

63. The delivery system of claim 62, wherein each of said plurality of stratum corneum-piercing microprojections has a length less than approximately 500 microns.

64. The delivery system of claim 62, wherein each of said plurality of stratum corneum-piercing microprojections has a thickness in the range of approximately 5-50 microns.

65. The delivery system of claim 62, wherein said compressible ring comprises a compressible foam.

66. The delivery system of claim 65, wherein said foam comprises a material selected from the group consisting of polyethylene, polyurethane, neoprene, natural rubber, SPR, butyl, butadiene, nitrile, EPDM, ECH, polystyrene, polyester, polyether, polypropylene, EVE, EMA, metallocene resin, PVC, and blends thereof.

67. The delivery system of claim 62, wherein said microprojection member is coated with a biocompatible coating, said biocompatible coating including at least one biologically active agent.

68. The delivery system of claim 67, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

69. The delivery system of claim 67, wherein each of said plurality of stratum corneum-piercing microprojections includes in the range of 1 microgram to 1 milligram of said biologically active agent.

70. The delivery system of claim 62, wherein said microprojection member includes a reservoir.

71. The delivery system of claim 70, wherein said reservoir includes at least one biologically active agent.

72. The delivery system of claim 71, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

73. The delivery system of claim 62, wherein said microprojection member includes an agent-containing matrix.

74. The delivery system of claim 73, wherein said matrix is disposed proximate said top surface of said microprojection member.

75. The delivery system of claim 73, wherein said matrix is disposed proximate said skin distal surface of said microprojection member.

76. The delivery system of claim 73, wherein said matrix includes at least one biologically active agent.

77. The delivery system of claim 76, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

78. A transdermal delivery system, comprising:

a microprojection member having a top surface and a skin distal surface, said microprojection member including a plurality of stratum corneum-piercing microprojections that project from said skin distal surface of said microprojection member; and

an applicator adapted to apply said microprojection member, said applicator including an applicator tip having a skin distal surface that is adapted to contact said microprojection member when said applicator is employed to apply said microprojection member, said applicator tip including a compressible member disposed on said skin distal surface of said applicator tip.

79. The delivery system of claim 78, wherein said applicator tip includes a substantially continuous recessed region on said skin distal surface of said applicator tip.

80. The delivery system of claim 79, wherein said compressible member is disposed in said recessed region.

81. The delivery system of claim 78, wherein said compressible member comprises a compressible foam.

82. The delivery system of claim 81, wherein said foam comprises a material selected from the group consisting of polyethylene, polyurethane, neoprene, natural rubber, SPR, butyl, butadiene, nitrile, EPDM, ECH, polystyrene, polyester, polyether, polypropylene, EVE, EMA, metallocene resin, PVC, and blends thereof.

83. The delivery system of claim 78, wherein said microprojection member is coated with a biocompatible coating, said biocompatible coating including at least one biologically active agent.

84. The delivery system of claim 83, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

85. The delivery system of claim 83, wherein each of said plurality of stratum corneum-piercing microprojections includes in the range of 1 microgram to 1 milligram of said biologically active agent.

86. The delivery system of claim 78, wherein said microprojection member includes a reservoir.

87. The delivery system of claim 86, wherein said reservoir includes at least one biologically active agent.

88. The delivery system of claim 87, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

89. The delivery system of claim 78, wherein said microprojection member includes an agent-containing matrix.

90. The delivery system of claim 89, wherein said matrix is disposed proximate said top surface of said microprojection member.

91. The delivery system of claim 89, wherein said matrix is disposed proximate said skin distal surface of said microprojection member.

92. The delivery system of claim 89, wherein said matrix includes at least one biologically active agent.

93. The delivery system of claim 92, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

94. A transdermal delivery system, comprising:

a microprojection member having a top surface and a skin distal surface, said microprojection member including a plurality of stratum corneum-piercing microprojections that project from said skin distal surface of said microprojection member, a substantially rigid matrix member disposed on said microprojection member top surface, a first compressible member disposed on said microprojection member top surface and surrounding said rigid matrix member, and a backing membrane disposed on said rigid matrix member and first compressible member; and

an applicator adapted to apply said microprojection member, said applicator including an applicator tip having a skin distal surface that is adapted to contact said microprojection member when said applicator is employed to apply said microprojection member, said applicator tip including a second compressible member disposed on said skin distal surface of said applicator tip.

95. The delivery system of claim 94, wherein each of said plurality of stratum corneum-piercing microprojections has a length less than approximately 500 microns.

96. The delivery system of claim 94, wherein each of said plurality of stratum corneum-piercing microprojections has a thickness in the range of approximately 5-50 microns.

97. The delivery system of claim 94, wherein said applicator tip includes a substantially continuous recessed region on said skin distal surface of said applicator tip.

98. The delivery system of claim 97, wherein said second compressible member is disposed in said recessed region.

99. The delivery system of claim 94, wherein said first and second compressible members comprise a compressible foam.

100. The delivery system of claim 99, wherein said foam comprises a material selected from the group consisting of polyethylene, polyurethane, neoprene, natural rubber, SPR, butyl, butadiene, nitrile, EPDM, ECH, polystyrene, polyester, polyether, polypropylene, EVE, EMA, metallocene resin, PVC, and blends thereof.

101. The delivery system of claim 94, wherein said microprojection member is coated with a biocompatible coating, said biocompatible coating including at least one biologically active agent.

102. The delivery system of claim 101, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

103. The delivery system of claim 101, wherein each of said plurality of stratum corneum-piercing microprojections includes in the range of 1 microgram to 1 milligram of said biologically active agent.

104. The delivery system of claim 94, wherein said microprojection member includes a reservoir.

105. The delivery system of claim 104, wherein said reservoir includes at least one biologically active agent.

106. The delivery system of claim 105, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.

107. The delivery system of claim 94, wherein said microprojection member includes an agent-containing matrix.

108. The delivery system of claim 107, wherein said matrix is disposed proximate said top surface of said microprojection member.

109. The delivery system of claim 107, wherein said matrix is disposed proximate said skin distal surface of said microprojection member.

110. The delivery system of claim 107, wherein said matrix includes at least one biologically active agent.

111. The delivery system of claim 110, wherein said biologically active agent is selected from the group consisting of ACTH (1-24), calcitonin, desmopressin, LHRH, LHRH analogs, goserelin, leuprolide, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, buserelin, triptorelin, interferon alpha, interferon beta, interferon gamma, FSH, EPO, GM,-CSF, G-CSF, IL-10, glucagon, growth hormone releasing factor (GRF) and analogs thereof, including pharmaceutically acceptable salts, conventional vaccines, recombinant protein vaccines, DNA vaccines and therapeutic cancer vaccines.